Humacyte, Inc.
HUMA
$1.29
$0.032.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -14.29% | -2.85% | 2.94% | 15.74% | 23.55% |
| Gross Profit | 16.09% | 3.82% | -2.29% | -15.74% | -23.55% |
| SG&A Expenses | 27.16% | 32.65% | 39.82% | 26.53% | 20.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.92% | 4.84% | 10.41% | 18.01% | 22.88% |
| Operating Income | 6.31% | -4.07% | -9.90% | -18.01% | -22.88% |
| Income Before Tax | 75.82% | 58.00% | 26.52% | -34.24% | -71.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 75.82% | 58.00% | 26.52% | -34.24% | -71.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 75.82% | 58.00% | 26.52% | -34.24% | -71.01% |
| EBIT | 6.31% | -4.07% | -9.90% | -18.01% | -22.88% |
| EBITDA | 6.89% | -4.29% | -10.91% | -20.16% | -26.01% |
| EPS Basic | 83.52% | 65.29% | 33.34% | -17.93% | -54.99% |
| Normalized Basic EPS | 37.99% | 25.49% | 17.76% | -3.03% | -15.09% |
| EPS Diluted | 83.34% | 65.17% | 32.59% | -18.35% | -55.51% |
| Normalized Diluted EPS | 38.00% | 25.51% | 17.77% | -3.03% | -15.09% |
| Average Basic Shares Outstanding | 27.07% | 22.78% | 18.76% | 14.54% | 9.00% |
| Average Diluted Shares Outstanding | 27.13% | 22.84% | 18.82% | 14.54% | 9.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |